Featured Research

from universities, journals, and other organizations

Immune therapy for advanced bladder cancer yields promising results

Date:
May 31, 2014
Source:
Yale University
Summary:
A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. The trial included 68 people with previously treated advanced bladder cancer, including 30 patients identified as PD-L1 positive. PD-L1 is a protein expressed by many tumor types that can render the cancer invulnerable to immune attack.

A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Yale Cancer Center played a key role in the study, the results of which will be presented Saturday, May 31 at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago.

Related Articles


The trial included 68 people with previously treated advanced bladder cancer, including 30 patients identified as PD-L1 positive. PD-L1 is a protein expressed by many tumor types that can render the cancer invulnerable to immune attack. The patients in the study were treated with MPDL3280A, a drug being developed by Genentech, a member of the Roche group.

At six weeks, the objective response rate (ORR) was 43%; at 12 weeks, the ORR was 52% in patients with PD-L1-positive tumors. A complete response -- one showing no evidence of tumors -- was seen in 7% of PD-L1 patients. In patients with PD-L1-negative tumors, the response rate was 11%.

The results in advanced bladder cancer patients "point to a new era in cancer treatment for a disease that has not seen a major advancement since the introduction of cisplatin-based combination therapy in the 1980s," said the study's senior author Daniel P. Petrylak, M.D., professor of medicine and urology at Yale Cancer Center and Yale School of Medicine. "We look forward to opening the phase II trial at Yale in June to confirm these findings."

Yale Cancer Center enrolled 12 of the 68 patients on the trial at Smilow Cancer Hospital at Yale-New Haven.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Immune therapy for advanced bladder cancer yields promising results." ScienceDaily. ScienceDaily, 31 May 2014. <www.sciencedaily.com/releases/2014/05/140531090724.htm>.
Yale University. (2014, May 31). Immune therapy for advanced bladder cancer yields promising results. ScienceDaily. Retrieved February 1, 2015 from www.sciencedaily.com/releases/2014/05/140531090724.htm
Yale University. "Immune therapy for advanced bladder cancer yields promising results." ScienceDaily. www.sciencedaily.com/releases/2014/05/140531090724.htm (accessed February 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, February 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Hikers Rescued After Fall from Oregon Mountain

Hikers Rescued After Fall from Oregon Mountain

AP (Feb. 1, 2015) Two climbers who were hurt in a fall on Mount Hood are now being treated for their injuries. Rescue officials say they were airlifted off the mountain Saturday afternoon by an Oregon National Guard helicopter. (Feb. 2) Video provided by AP
Powered by NewsLook.com
Smart Glasses Augment Reality to Help Visually Impaired

Smart Glasses Augment Reality to Help Visually Impaired

Reuters - Innovations Video Online (Feb. 1, 2015) New augmented reality smart glasses developed by researchers at Oxford University can help people with visual impairments improve their vision by providing depth-based feedback, allowing users to "see" better. Joel Flynn reports. Video provided by Reuters
Powered by NewsLook.com
Flu Season Hitting Elderly Hard

Flu Season Hitting Elderly Hard

Reuters - US Online Video (Jan. 31, 2015) The CDC says this year&apos;s flu season is hitting people 65 years of age and older especially hard. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
CDC: Get Vaccinated for Measles

CDC: Get Vaccinated for Measles

Reuters - US Online Video (Jan. 30, 2015) The CDC is urging people to get vaccinated for measles amid an outbreak that began at Disneyland and has now infected more than 90 people. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins